Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

Hyperion Therapeutics enrolls first patient in HPN-100 trial in children with urea cycle disorders

Sep. 18, 2009

DNage initiates observational study in children with Cockayne syndrome

Sep. 18, 2009

ONO-5334 shows potential for osteoporosis therapy in ovariectomized monkeys

Sep. 18, 2009

ACE-011 active against bone loss in postmenopausal women

Sep. 18, 2009

Follicle-stimulating hormone receptor activators for female infertility disclosed by Organon

Sep. 17, 2009

Protalix BioTherapeutics completes pivotal phase III prGCD trial for Gaucher's disease

Sep. 17, 2009

Diabetes Research Centers collaborate on phase II Exsulin trial

Sep. 17, 2009

QuatRx reports results of second pivotal phase III study of Ophena

Sep. 16, 2009

Affymax provides update for phase III Hematide program in chronic renal failure

Sep. 16, 2009

S-equol efficacious in rat osteoporosis model

Sep. 15, 2009

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 18, 2026.
GLP-1s need technologies for long-term use
BioWorld
For the long-term impact of GLP-1 therapies in obesity to be realized, they must be paired with data and digital tools. While the drugs are effective, challenges...
UTRN gene involved in arthrogryposis, study finds
BioWorld Science
Arthrogryposis multiplex congenita (AMC) is a group of disorders defined by two or more contractures in different body areas; while genes encoding sarcomeric...
HMNC raises $50M series B to prep depression drugs for phase III
BioWorld
HMNC Brain Health GmbH has raised $50 million in the first close of a series B, enabling the company to prepare the way for phase III trials of its two lead...
CFTX-2034 successfully shows promise for post-bariatric hypoglycemia in preclinical research
BioWorld Science
Researchers from Confo Therapeutics NV presented the preclinical characterization of CFTX-2034, a selective somatostatin receptor subtype 5 (SSTR5) agonist...